Adult genetic risk screening

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 1-17

  Caskey, C Thomas ^a   Gonzalez Garay, Manuel L ^b   Pereira, Stacey ^a   McGuire, Amy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Disease prediction; Genetic counseling; Genomics; Incidental findings; Molecular medicine; Whole exome sequencing

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIZZY RELATED PROTEIN; PROTEIN; PROTEIN KINASE LKB1; PROTEIN P53; RAD50 PROTEIN; RAD51 PROTEIN; UNCLASSIFIED DRUG; XRCC2 PROTEIN; XRCC3 PROTEIN;

ADULT; ALZHEIMER DISEASE; ANEURYSM; ARTICLE; ATAXIA; BIOINFORMATICS; BRAIN ISCHEMIA; BREAST CANCER; CANCER RISK; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; COLON CANCER; DNA SEQUENCE; ELECTRONIC MEDICAL RECORD; FAMILIAL HYPERCHOLESTEROLEMIA; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; INTERPERSONAL COMMUNICATION; MARFAN SYNDROME; MEDICAL CARE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY CANCER; PANCREAS CANCER; PARKINSON DISEASE; PEDIGREE; PRIORITY JOURNAL;

ADULT; CARDIOVASCULAR DISEASES; DATABASES, GENETIC; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; OBESITY; PRIMARY PREVENTION; RISK ASSESSMENT; SEQUENCE ANALYSIS, DNA;

EID: 84901622632     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-111212-144716     Document Type: Article

References (103)

1. McCabe LL, McCabe ER. 2008. Expanded newborn screening: implications for genomic medicine. Annu. Rev. Med. 59:163-75 (Pubitemid 351287930)
2. Watson MS, MannMY, Lloyd-Puryear MA, et al. 2006. Newborn screening: toward a uniform screening panel and system-executive summary. Pediatrics 117:S296-307
3. Kaback M, Lopatequi J, Portuges AR, et al. 2010. Genetic screening in the Persian Jewish community: a pilot study. Genet. Med. 12:628-33
4. Scott SA, Edelmann L, Liu L, et al. 2010. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum. Mutat. 31:1240-50
5. Bell CJ, Dinwiddie DL, Miller NA, et al. 2011. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci. Transl. Med. 3:65ra4
6. Kingsmore S. 2012. Comprehensive carrier screening and molecular diagnostic testing for recessive childhood diseases. PLoS Curr. 4:e4f9877ab8ffa9
7. Laberge AM, Watts C, Porter K, et al. 2010. Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and β-thalassemia. Public Health Genomics 13:310-19
8. Chiu RW, Lo YM. 2012. Noninvasive prenatal diagnosis empowered by high-throughput sequencing. Prenat. Diagn. 32:401-6
9. Papasavva T, van Ijcken WF, Kockx CE, et al. 2013. Next generation sequencing of SNPs for noninvasive prenatal diagnosis: challenges and feasibility as illustrated by an application to β-thalassaemia. Eur. J. Hum. Genet. In press. doi: 10.1038/ejhg.2013.47
10. Butte AJ, Green R. 2013. Should healthy people have their genomes sequenced at this time? Wall Street J. Feb. 15. http://online.wsj.com/article/ SB10000872396390443884104577645783975993656.html
11. Lander ES, Linton LM, Birren B, et al. 2001. Initial sequencing and analysis of the human genome. Nature 409:860-921 (Pubitemid 32165345)
12. Leung YF, Cavalieri D. 2003. Fundamentals of cDNA microarray data analysis. Trends Genet. 19:649-59 (Pubitemid 37338385)
13. Beaudet AL, Belmont JW. 2008. Array-based DNA diagnostics: let the revolution begin. Annu. Rev. Med. 59:113-29 (Pubitemid 351287927)
14. Bi W, Borgan C, Pursley AN, et al. 2013. Comparison of chromosome analysis and chromosomal microarray analysis: What is the value of chromosome analysis in today's genomic array era? GenetMed. 15:450-57
15. Burton M, ThomassenM, Tan Q, et al. 2012. Gene expression profiles for predictingmetastasis in breast cancer: a cross-study comparison of classification methods. Sci. World J. 2012:(ID 380495):1-11
16. Moldovan L, Mitroi A, Petrescu C, et al. 2013. Classification of breast carcinomas according to gene expression profiles. J. Med. Life 6:14-17
17. Allyse M, Michie M. 2013. Not-so-incidental findings: theACMGrecommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing. Trends Biotechnol. 31(8):439- 41
18. Liu L, Li Y, Li S, et al. 2012. Comparison of next-generation sequencing systems. J. Biomed. Biotechnol. 2012:251364
19. Berglund EC, Kiialainen A, Syvanen AC. 2011. Next-generation sequencing technologies and applications for human genetic history and forensics. Investig. Genet. 2:23
20. Pennisi E. 2003. Bioinformatics. Gene counters struggle to get the right answer. Science 301:1040-41 (Pubitemid 37022292)
21. Stenson PD, Mort M, Ball EV, et al. 2009. The Human Gene Mutation Database: 2008 update. Genome Med. 1:13
22. Widmer C, Deshazo JP, Bodurtha J, et al. 2013. Genetic counselors' current use of personal health records-based family histories in genetic clinics and considerations for their future adoption. J. Genet. Couns. 22:384-92
23. Peng G, Fan Y, Palculict TB, et al. 2013. Rare variant detection using family-based sequencing analysis. Proc. Natl. Acad. Sci. USA 110:3985-90
24. Albert TJ, Molla MN, Muzny DM, et al. 2007. Direct selection of human genomic loci by microarray hybridization. Nat. Methods 4:903-5 (Pubitemid 350042375)
25. Kemena C, Notredame C. 2009. Upcoming challenges for multiple sequence alignment methods in the high-throughput era. Bioinformatics 25:2455-65
26. Li H, HomerN. 2010. A survey of sequence alignment algorithms for next-generation sequencing. Brief. Bioinform. 11:473-83
27. Altmann A, Weber P, Bader D, et al. 2012. A beginners guide to SNP calling from high-throughput DNA-sequencing data. Hum. Genet. 131:1541-54
28. Tavtigian SV, Greenblatt MS, Lesueur F, et al. 2008. In silico analysis of missense substitutions using sequence-alignment based methods. Hum. Mutat. 29:1327-36
29. Minoche AE, Dohm JC, Himmelbauer H. 2011. Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol. 12:R112
30. Drmanac R, Sparks AB, Callow MJ, et al. 2010. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327:78-81
31. Roach JC, Glusman G, Smit AF, et al. 2010. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 328:636-39
32. Lee H, Schatz MC. 2012. Genomic dark matter: the reliability of short read mapping illustrated by the Genome Mappability Score. Bioinformatics 28:2097-105
33. Bloss CS, Darst BF, Topol EJ, et al. 2011. Direct-to-consumer personalized genomic testing. Hum. Mol. Genet. 20:R132-41
34. Ball MP, Thakuria JV, Zaranek AW, et al. 2012. A public resource facilitating clinical use of genomes. Proc. Natl. Acad. Sci. USA 109:11920-27
35. Facio FM, Eidem H, Fisher T, et al. 2013. Intentions to receive individual results from whole-genome sequencing among participants in the ClinSeq study. Eur. J. Hum. Genet. 21:261-65
36. Biesecker LG. 2013. Incidental variants are critical for genomics. Am. J. Hum. Genet. 92:648-51
37. Gonzalez-Garay ML, McGuire AL, Pereira S, Caskey CT. 2013. Personalized genomic disease risk of volunteers. Proc. Natl. Acad. Sci. USA. 110:16957-62
38. Green RC, Berg JS, Grody WW, et al. 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15:565-74
39. Minino AM, Murphy SL, Xu J, et al. 2011. Deaths: final data for 2008. Natl. Vital Stat. Rep. 59:1-126
40. Fokstuen S, Makrythanasis P, Nikolaev S, et al. 2013. Multiplex targeted high-throughput sequencing for Mendelian cardiac disorders. Clin. Genet. In press. doi: 10.1111/cge.12168
41. Cariou B, Le May C, Costet P. 2011. Clinical aspects of PCSK9. Atherosclerosis 216:258-65
42. Goldberg AS, Hegele RA. 2012. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Des. Dev. Ther. 6:251-59
43. Phan BA, Dayspring TD, Toth PP. 2012. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag. 8:415-27
44. Grigore L, Norata GD, Catapano AL. 2008. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc. Health Risk Manag. 4:267-78 (Pubitemid 351711955)
45. von Kodolitsch Y, Robinson PN. 2007. Marfan syndrome: an update of genetics, medical and surgical management. Heart 93:755-60 (Pubitemid 46808288)
46. Loeys BL, Chen J, Neptune ER, et al. 2005.Asyndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 37:275-81 (Pubitemid 41716254)
47. Yang X. 2003. Imaging of vascular gene therapy. Radiology 228:36-49 (Pubitemid 36736067)
48. Diez J. 2006. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. Clin. Ther. 28:832-48 (Pubitemid 44062691)
49. WatkinsH, McKenna WJ, Thierfelder L, et al. 1995. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332:1058-64
50. Lopes LR, Rahman MS, Elliott PM. 2013. A systematic review andmeta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. In press
51. Morales A, Hershberger RE. 2013. Genetic evaluation of dilated cardiomyopathy. Curr. Cardiol. Rep. 15:375
52. Giudicessi JR, Ackerman MJ. 2012. Potassium-channel mutations and cardiac arrhythmias-diagnosis and therapy. Nat. Rev. Cardiol. 9:319-32
53. Napolitano C, Bloise R, Monteforte N, et al. 2012. Sudden cardiac death and genetic ion channelopathies: long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation. Circulation 125:2027-34
54. King CS, Holley AB, Moores LK. 2013. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. Chest 143:1106-16
55. Gurbel PA, Tantry US. 2012. Do platelet function testing and genotyping improve outcome in patients treatedwith antithrombotic agentsPlatelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 125:1276-87; discussion 87
56. Johnson JA, Gong L, Whirl-Carrillo M, et al. 2011. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90:625-29
57. Nahar R, Dube D, Parakh R, et al. 2013. Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity. Thromb. Res. 131(6):535-39
58. Anton AI, Cerezo-Manchado JJ, Padilla J, et al. 2013. Novel associations of VKORC1 variants with higher acenocoumarol requirements. PLoS ONE 8:e64469
59. Ong FS, Deignan JL, Kuo JZ, et al. 2012. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics 13:465-75
60. Samer CF, Lorenzini KI, Rollason V, et al. 2013. Applications of CYP450 testing in the clinical setting. Mol. Diagn. Ther. 17:165-84
61. Knudson AG Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68:820-23
62. Futreal PA, Liu Q, Shattuck-Eidens D, et al. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-22 (Pubitemid 24345332)
63. Miki Y, Swensen J, Shattuck-Eidens D, et al. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71 (Pubitemid 24345325)
64. Wooster R, Bignell G, Lancaster J, et al. 1995. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-92 (Pubitemid 26004412)
65. Stadler ZK, Salo-Mullen E, Patil SM, et al. 2012. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 118:493-99
66. Mavaddat N, Peock S, Frost D, et al. 2013. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 105:812-22
67. Semple J, Metcalfe KA, Lynch HT, et al. 2013. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. Ann. Surg. Oncol. 20:3817-22
68. Jolie A. 2013. My medical choice. New York Times, May 14, Opinion. http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html-r=1&
69. Futreal PA. 2007. Backseat drivers take the wheel. Cancer Cell 12:493-94 (Pubitemid 350199076)
70. Ithimakin S, Day KC, Malik F, et al. 2013. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 73:1635-46
71. Silva FC, Valentin MD, Ferreira Fde O, et al. 2009. Mismatch repair genes in Lynch syndrome: a review. Sao Paulo Med. J. 127:46-51
72. Steinke V, Engel C, Buttner R, et al. 2013. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. Dtsch. Arztebl. Int. 110:32-38
73. Finkelstein SD, Sayegh R, Bakker A, et al. 1993. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch. Surg. 128:526-31; discussion 31-32
74. Savas S, Younghusband HB. 2010. dbCPCO: a database of genetic markers tested for their predictive and prognostic value in colorectal cancer. Hum. Mutat. 31:901-7
75. Zhang X, Leav I, Revelo MP, et al. 2009. Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet. 5:e1000334
76. Collet JP, Sharpe C, Belzile E, et al. 1999. Colorectal cancer prevention by non-steroidal antiinflammatory drugs: effects of dosage and timing. Br. J. Cancer 81:62-68 (Pubitemid 29415492)
77. Fu Z, Shrubsole MJ, Smalley WE, et al. 2012. Lifestyle factors and their combined impact on the risk of colorectal polyps. Am. J. Epidemiol. 176:766-76
78. Mokdad AH, Bowman BA, Ford ES, et al. 2001. The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-200 (Pubitemid 33015548)
79. Wang X, Ding X, Su S, et al. 2009. Heritability of insulin sensitivity and lipid profile depend on BMI: evidence for gene-obesity interaction. Diabetologia 52:2578-84
80. Roche SL, Silversides CK. 2013. Hypertension, obesity, and coronary artery disease in the survivors of congenital heart disease. Can. J. Cardiol. 29(7):841-48
81. Williams SC. 2013. Link between obesity and cancer. Proc. Natl. Acad. Sci. USA 110:8753-54
82. Basen-Engquist K, Chang M. 2011. Obesity and cancer risk: recent review and evidence. Curr. Oncol. Rep. 13:71-76
83. Alshehri AM. 2010. Metabolic syndrome and cardiovascular risk. J. Fam. Community Med. 17:73-78
84. Paracchini V, Pedotti P, Taioli E. 2005. Genetics of leptin and obesity: aHuGE review. Am. J. Epidemiol. 162:101-14 (Pubitemid 41373535)
85. Nan C, Guo B, Warner C, et al. 2012. Heritability of body mass index in pre-adolescence, young adulthood and late adulthood. Eur. J. Epidemiol. 27:247-53
86. Rankinen T, Zuberi A, Chagnon YC, et al. 2006. The human obesity gene map: the 2005 update. Obesity (Silver Spring) 14:529-644 (Pubitemid 46219737)
87. El-Sayed Moustafa JS, Froguel P. 2013. From obesity genetics to the future of personalized obesity therapy. Nat. Rev. Endocrinol. 9(7):402-13
88. CosentinoG, Conrad AO, Uwaifo GI. 2013. Phentermine and topiramate for the management of obesity: a review. Drug Des. Dev. Ther. 7:267-78
89. Himpens JM. 2008. Gastric banding-to band or bypass. Adjustable gastric banding: blessing or curse? Ann. R. Coll. Surg. Engl. 90:2-4 (Pubitemid 351227927)
90. Ross CA, Tabrizi SJ. 2011. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10:83-98
91. Tanzi RE. 2012. The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. In press. doi: 10.1101/cshperspect.a006296
92. Bertram L, Lill CM, Tanzi RE. 2010. The genetics of Alzheimer disease: back to the future. Neuron 68:270-81
93. Galimberti D, Scarpini E. 2013. Progress in Alzheimer's disease research in the last year. J. Neurol. 260(7):1936-41
94. Zawieja P, Kornprobst JM, Metais P. 2012. 3-(2, 4-Dimethoxybenzylidene)- anabaseine: a promising candidate drug for Alzheimer's disease? Geriatr. Gerontol. Int. 12:365-71
95. Herborn CU, Honold E, Wolf M, et al. 2007. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Investig. Radiol. 42:58-62 (Pubitemid 46072553)
96. Santin MD, Debeir T, Bridal SL, et al. 2013. Fast in vivo imaging of amyloid plaques using μ-MRI Gd-staining combined with ultrasound-induced blood-brain barrier opening. Neuroimage 79C:288-94
97. Monaca-Charley C, Stojkovic T, Duhamel A, et al. 2003. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J. Neurol. 250:1190-94 (Pubitemid 37289650)
98. Biesecker LG. 2012. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet. Med. 14:393-98
99. Johnston JJ, Rubinstein WS, Facio FM, et al. 2012. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am. J. Hum. Genet. 91:97-108
100. Biesecker LG, Mullikin JC, Facio FM, et al. 2009. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res. 19:1665-74
101. Facio FM, Brooks S, Loewenstein J, et al. 2011. Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. Eur. J. Hum. Genet. 19:1213-17
102. Solomon BD, Nguyen AD, Bear KA, et al. 2013. Clinical Genomic Database. Proc. Natl. Acad. Sci. USA 11;110(24):9851-55
103. Fokkema IF, Taschner PE, Schaafsma GC, et al. 2011. LOVD v.2.0: the next generation in gene variant databases. Hum. Mutat. 32:557-63